Browse studies

Find your next paid study

699 recruiting studies matching your filters

A Phase III, Randomized, Open-label Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy as First-Line Therapy in Patients With EGFR-Mutant Locally Advanced or Metastatic Non-small Cell Lung Cancer

The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanc…

Non-Small Cell Lung Cancer

Estimated

~$10 – $7,500

Bristol-Myers SquibbNCT07680790

Observational

Empathic Communication Skills Training to Reduce Lung Cancer Stigma

Research indicates that perceived stigma within medical encounters is prevalent and problematic for lung cancer patients' well-being and quality of cancer care…

Lung Cancer

Estimated

~$10 – $6,250

Memorial Sloan Kettering Cancer CenterNCT05456841

Phase 2

IIT2022-05-Sankar-BELIEVE: Phase II Study of Bevacizumab in Combination With Chemoimmunotherapy and Maintenance Atezolizumab in Patients With Extensive Stage Small Cell Lung Cancer and Liver Metastases

This clinical trial aims to assess whether the addition of bevacizumab to atezolizumab and chemotherapy can improve response to treatment and progression-free …

Extensive-stage Small-cell Lung CancerLiver Metastases

Estimated

~$10 – $7,500

Kamya SankarNCT05588388

Observational

Information Needs, Preferences, and Understanding Trial (INPUT): A Randomized, Controlled Trial of the Effects of a Screening Tool on Illness Understanding

This clinical trial compares the use of a new screening tool designed to evaluate patients' information needs, preferences, and illness understanding to the us…

Lung CarcinomaMetastatic Lung CarcinomaStage IV Lung Cancer AJCC v8

Estimated

~$10 – $6,250

M.D. Anderson Cancer CenterNCT06743308

Prospective Evaluation of Genetic and Epigenetic Alterations in Patients With Thoracic Malignancies

Background: * Chromatin is is the structural building block of a chromosome. It is found inside the nucleus of the cell and consists of a complex of DNA and p…

Thoracic CancersMalignant Pleural Mesotheliomas NOSLung Cancer NOS+3 more

Estimated

~$10 – $675

National Cancer Institute (NCI)NCT00242723

Phase 3

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small …

Lung Non-Small Cell CarcinomaLung Non-Small Cell Squamous CarcinomaLung Non-Squamous Non-Small Cell Carcinoma+3 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04267848

Phase 1

A Phase 1 First-In-Human Study to Investigate the Safety, Pharmacokinetics and Preliminary Efficacy of ML261, an Autologous Anti-DLL3 CAR + CARD11-PIK3R3 Fusion T Cell Therapy, in Participants With Relapsed/Refractory Small Cell Lung Cancer or Select Neuroendocrine Carcinomas

This is a first-in-human (FIH), open-label, Phase 1 study designed to evaluate the safety, pharmacokinetics (PK), and preliminary efficacy of ML261, an autolog…

Small Cell Lung Cancer (SCLC )Extrapulmonary Neuroendocrine Carcinoma (EP-NEC)Gastroenteropancreatic NEC (GEP NEC)+1 more

Estimated

~$10 – $8,750

Moonlight Bio, IncNCT07488923

Phase 1

Phase I Clinical Trial of Autologous Folate Receptor-Alpha Redirected T Cells in Patients With FRa+ Cancers

This is a Phase I open-label clinical trial to assess the safety, feasibility, and preliminary efficacy of intrapleural administration of MOv19-BBz CAR T cells…

Metastatic Non Small Cell Lung CancerRecurrent Lung Non-Small Cell Carcinoma

Estimated

~$10 – $6,250

University of PennsylvaniaNCT07116057

Phase 1

A Phase 1 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BL-M07D1 in Subjects With HER2 Expressing Advanced Malignant Solid Tumors

The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

Endometrial CancerCervical CancerOvarian Cancer+7 more

Estimated

~$10 – $8,750

SystImmune Inc.NCT06293898

Registry Trial and Needs Assessment of Patients With Young-onset Lung Cancer: Impact of a Dedicated Care Program on Patient Experience and Outcomes

The goal of this research study is to learn about: The effect of enrolling in the YOLC program on patient satisfaction with care provided, The needs of patie…

Lung Cancer

Estimated

~$10 – $750

M.D. Anderson Cancer CenterNCT07220096

Phase 3

A Phase III, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Patients With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or c…

Non-Small Cell Lung CancerKRAS G12C Lung Cancer

Estimated

~$10 – $7,500

Hoffmann-La RocheNCT06793215

Phase 2

A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients With Previously Treated, Advanced KRAS G12D-Mutated Non-Small Cell Lung Cancer (TARGET-D 202)

This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cel…

Non-Small Cell Lung Cancer

Estimated

~$10 – $8,750

Verastem, Inc.NCT07659782